Shanghai Shen Lian Biomedical Corp (688098) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Shanghai Shen Lian Biomedical Corp ¥1.99, price ¥8.68, upside -77.1%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Shen Lian Biomedical Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥3.67 – ¥15.40 · fair‑value band ¥1.57 – ¥2.41 · the ¥8.68 price screens above the ¥1.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Shanghai Shen Lian Biomedical in your weekly email
Every Wednesday you see whether Shanghai Shen Lian Biomedical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Shen Lian Biomedical Corp (688098) currently trades at ¥8.68, while our model-based Fair Value estimate is ¥1.99, implying the stock looks roughly 336.1% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥2.27 per share, and 0 of the 5 models we run sit above the ¥8.68 price.
Bear case: the DCF Models group reads lowest at ¥0.6000, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.57 (bear) to ¥2.41 (bull), the price of ¥8.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shanghai Shen Lian Biomedical Corp reported revenue of 288M CNY in FY2025 versus 358M CNY in FY2021, a compound −5.3%/yr. Reported net income was −19.1M CNY in FY2025.
Key figures
Market cap 3.6B CNY (≈ $536M) · P/S ratio 12.9 · EPS (TTM) ¥−0.0400 · Net margin −6.6% · Return on equity −1.2% · Return on assets (EBIT) 1.9% · Operating margin −3.6% · Revenue (TTM) 272M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −77%, 688098 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0100 to ¥2.27). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥1.57Fair Value ¥1.99Bull ¥2.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
43.6% (2020) → −9.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Shanghai Shen Lian Biomedical Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−77% · Bottom 25%
Profitability
Return on assets−1% · Above median
Net margin (TTM)−7% · Below median
Operating margin (TTM)−4% · Below median
Growth and dividend
Revenue growth−21% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.39× · Cheapest 25%
P/S (TTM)1.97× · Cheaper than median
EV/EBITDA8.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Shen Lian Biomedical Corp Fair Value". https://www.fairvalue-calculator.com/stock/688098
Frequently asked questions
Is Shanghai Shen Lian Biomedical Corp (688098) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥1.99 versus a price of ¥8.68, about −77% upside (overvalued).
What is the fair value of 688098?
Our model-based fair value for Shanghai Shen Lian Biomedical Corp is ¥1.99 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥8.68.
What is the quality score of 688098?
Shanghai Shen Lian Biomedical Corp has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Shen Lian Biomedical Corp (688098)?
Our model-based price target is the fair value of ¥1.99 (as of Sep 23, 2026) from 5 valuation models. Cautious scenario ¥1.57, optimistic scenario ¥2.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Shen Lian Biomedical Corp stock forecast for 2026?
Our models put fair value at ¥1.99, about −77% upside versus a price of ¥8.68 (overvalued). Cautious scenario ¥1.57, optimistic scenario ¥2.41. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Shen Lian Biomedical Corp (688098)?
Shanghai Shen Lian Biomedical Corp reported trailing-twelve-month revenue of about 272M CNY (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Shanghai Shen Lian Biomedical Corp (688098)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Shen Lian Biomedical Corp it is ¥1.99 per share (as of Sep 23, 2026), against a price of ¥8.68. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Shen Lian Biomedical Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688098 trades above its calculated fair value: price ¥8.68, fair value ¥1.99, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688098?
No. The price is what the market pays today (¥8.68); the fair value is what the company's own numbers justify (¥1.99). For Shanghai Shen Lian Biomedical Corp the two are ¥6.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Shen Lian Biomedical Corp worth?
The market values Shanghai Shen Lian Biomedical Corp at about 3.6B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥8.68; our models calculate a fair value of ¥1.99 per share.
What do the bullish and bearish scenarios say about 688098?
Our models span a range for Shanghai Shen Lian Biomedical Corp: cautious scenario ¥1.57, base ¥1.99, optimistic ¥2.41 per share (as of Sep 23, 2026, price ¥8.68). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Shen Lian Biomedical Corp (688098)?
Balance-sheet figures for Shanghai Shen Lian Biomedical Corp (as of Sep 23, 2026): return on equity −1.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 688098 from its 52-week high?
Shanghai Shen Lian Biomedical Corp trades at ¥8.68, about 24% below its 52-week high of ¥11.43 and 17% above the low of ¥7.39 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.99 is for.
Which stocks are comparable to Shanghai Shen Lian Biomedical Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Shen Lian Biomedical Corp stock attractive at the current price?
The data as of Sep 23, 2026: price ¥8.68, calculated fair value ¥1.99 (−77%), Quality Score 54/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688098 calculated?
We run Shanghai Shen Lian Biomedical Corp through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.99, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shanghai Shen Lian Biomedical Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Shen Lian Biomedical Corp (688098)?
The closing price on Sep 23, 2026 was ¥8.68. Our model-based fair value is ¥1.99, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Shen Lian Biomedical Corp right now?
The price sits above even our optimistic bull case (¥2.41). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shanghai Shen Lian Biomedical Corp
How large is the market capitalisation of Shanghai Shen Lian Biomedical Corp (688098)?
The market capitalisation of Shanghai Shen Lian Biomedical Corp is 3.6B CNY (≈ $536M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Shen Lian Biomedical Corp (688098)?
The price-to-sales ratio of Shanghai Shen Lian Biomedical Corp is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Shen Lian Biomedical Corp (688098)?
Earnings per share at Shanghai Shen Lian Biomedical Corp are ¥−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Shanghai Shen Lian Biomedical Corp (688098)?
The net margin of Shanghai Shen Lian Biomedical Corp is −6.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Shen Lian Biomedical Corp (688098)?
The return on equity (ROE) of Shanghai Shen Lian Biomedical Corp is −1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Shen Lian Biomedical Corp (688098)?
On an EBIT basis the return on assets of Shanghai Shen Lian Biomedical Corp is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Shen Lian Biomedical Corp (688098)?
The operating margin of Shanghai Shen Lian Biomedical Corp is −3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Shen Lian Biomedical Corp (688098)?
Revenue at Shanghai Shen Lian Biomedical Corp is growing −20.5% versus a year earlier (3y avg −4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Shen Lian Biomedical Corp (688098)?
Earnings per share at Shanghai Shen Lian Biomedical Corp are growing −13.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai Shen Lian Biomedical Corp (688098) generate?
The free cash flow of Shanghai Shen Lian Biomedical Corp is −12.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Shanghai Shen Lian Biomedical Corp (688098) hold?
Shanghai Shen Lian Biomedical Corp holds more cash than debt, 131M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Shen Lian Biomedical Corp in the live analysis
One click puts Shanghai Shen Lian Biomedical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
